Alexion, Pfizer Rise Premarket; Novartis Falls

Alexion, Pfizer Rise Premarket; Novartis Falls

© Reuters.  © Reuters.

By Peter Nurse — Stocks in focus in premarket trade on Monday, December 14th. Please refresh for updates.

  • Alexion (NASDAQ:ALXN) stock soared 31% after AstraZeneca (NASDAQ:AZN), down 5.6%, bid $39 billion for the U.S. biotech firm, the company's largest ever and one of this year's biggest mergers globally.

  • Pfizer (NYSE:PFE) stock rose 1.3% as the pharma giant’s Covid-19 vaccine is rolled out to the U.S. population, starting this week.

  • Novartis (NYSE:NVS) ADR fell 0.9% after the Swiss pharma company said that phase 3 of its Covid-19 treatment didn’t meet its primary objective of reducing the number of hospitalized patients.

  • Tesla (NASDAQ:TSLA) stock rose 1.4% with the electric carmaker set to join the benchmark S&P 500 index on Friday, prompting index funds to adjust their holdings.

  • Electronic Arts (NASDAQ:EA) stock rose 2.2% after the games maker reached an agreement on Monday to buy racing game developer Codemasters in a deal worth $1.2 billion.

  • SolarWinds (NYSE:SWI) stock fell 10% after the IT company said it may have been hit in a “highly-sophisticated, targeted and manual supply chain attack by a nation state.”

  • Snowflake (NYSE:SNOW) stock rose 1.1% ahead of Tuesday’s first opportunity for company insiders to cash out since the initial public offering three months ago.

  • Alphabet (NASDAQ:GOOGL) stock fell 0.4% after many of the company’s services, including YouTube, Gmail and Google Drive, were down for thousands of users across the globe on Monday.

  • CureVac (NASDAQ:CVAC) stock rose 6.7% after the biotech enrolled its first participant in a clinical trial for its Covid-19 vaccine candidate. CureVac said the study is expected to include more than 35,000 people in Europe and Latin America.

Original Article

Leave a comment

Send a Comment

Your email address will not be published.

Enter text shown below: